CAMP4 Therapeutics

CAMP4 Therapeutics

  • Founded: 2016
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Funding: $100M B Jul 2022; $45M A Jun 2021; $30M Jun 2018
  • Investors: Patient Square Capital, Gaingels, 5AM Ventures, Polaris Partners, Northpond Ventures, Andreessen Horowitz, The Kraft Group

job board

Short description:

4D Gene Circuitry Platform

Drug notes:

Contact us to add description:

Long description:

CAMP4 Therapeutics is developing programmable oligonucleotide therapeutics to regulate gene expression. Faulty gene expression underlies many human diseases with restoration of gene expression to normal levels being a path to treat them. CAMP4’s approach is to identify gene specific regulatory RNA targets for the tunable upregulation of genes. To target the RNAs, CAMP4 is designing RNA actuators - programmable antisense oligonucleotides - that can produce specific changes in protein expression. CAMP4 is designing RNA Actuators to treat diseases throughout the body. CAMP4’s initial focus is on diseases of the liver and central nervous system, but the technology has the potential to apply to every human tissue.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy